John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, ...

Arvinas on Wednesday said Houston, who has been president and chief executive of the New Haven, Conn., company since September 2017, will retire from those positions upon the appointment of a ...

Arvinas Inc., a New Haven-based biotechnology company, said Wednesday that its CEO and president plans to retire once a successor is found.

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

Arvinas, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates [email protected] (Simply Wall St) Sun, May 4, 2025, 8:36 AM3 min read ...

Shares of Arvinas, Inc. (ARVN) have gained 13.9% over the past four weeks to close the last trading session at $7.39, but there could still be a solid upside left in the stock if short-term price ...

Arvinas Inc. (NASDAQ:ARVN), a biotechnology company specializing in protein degradation therapeutics, stands at a critical juncture as it approaches the release of pivotal clinical trial data ...

Arvinas focuses on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. Read why we view ARVN stock as a Sell.

Arvinas reported positive Phase 3 trial results, new findings for ARV-102, and announced cost reductions including workforce layoffs.

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements.

About Arvinas Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases.